drugset / Trial / NCT01056172
PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
Phase 4
Unknown
164 enrolled
Pusan National University Yangsan Hospital
Incheon St.Mary's Hospital · collabInje University · collabInje University Haeundae Paik Hospital · collabInje University Ilsan Paik Hospital · collabPusan National University Hospital · collabSeverance Hospital · collabSoon Chun Hyang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aim to evaluate the non-inferiority of sustained virologic response in peginterferon alfa-2a and weight-based ribavirin for 16 weeks compare with standard treatment duration of 24 weeks in patients who achieved rapid virologic response with genotype 2 CHC.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-06
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
| Comparator | Ribavirin | Small molecule | 800 mg | — |
| Comparator | Ribavirin | Small molecule | 1000 mg | — |
| Comparator | Ribavirin | Small molecule | 1200 mg | — |